Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

Inclusion Criteria:

For ALL participants:

• Adults 18-80 years of age

• Weight ≥50kg and BMI between ≥18 to ≤40 kg/m2 For participants with normal hepaticfunction:

• Participant must be stable on a concomitant medication and/or treatment regimen forat least 2 weeks prior to screening

For Healthy Controls:

-Participant must be medically healthy with no significant findings on medical evaluation at screening to include but not limited to an eGFR >90 ml/min/1.73 m2

For participants with hepatic impairment:

• Group 1 (mild) must have an Child-Pugh score of 5 or 6, Group 2 (moderate) must havea Child-Pugh score of 7 to 9, Group 3 (severe) must have a Child-Pugh score of 10 to

• Participant must have a diagnosis of chronic (≥ 6 months) and stable hepaticimpairment (eg, no clinically significant change in signs, symptoms, or laboratoryparameters of hepatic disease status within 30 days prior to study screening

Exclusion Criteria:

For ALL participants:

• Poorly controlled diabetes mellitus (A1C >10% at screening).

• Unwillingness to use adequate contraception

• Uncontrolled hypertension or hypotension

• Presence of unstable systemic disease or psychologic conditions.

• Any clinically significant abnormalities in rhythm, conduction, or morphology of theresting ECG and any clinically important abnormalities in the 12-lead ECG.

Specific For Healthy Controls:

-Positive screening for HIV, Hepatitis B, or Hepatitis C -

-Any clinically significant disease or disorder to include but not limited to acute or chronic liver disease

Specific For Hepatically Impaired Participants:

• eGFR <60 ml/min/1.73 m2

• Fluctuating or rapidly deteriorating hepatic function, as indicated by stronglyvarying or worsening of clinical and/or laboratory signs of hepatic impairment toinclude rising LFTs, paracentesis at less than 4 week intervals, oesophageal bandingwithin the last 3 months, or treatment for GI bleeding within the last 6 months

• Presence of a hepatocellular carcinoma or acute liver disease caused by an infectionor drug toxicity.